Central nervous system relapse in high-risk stage 4 neuroblastoma: The HR-NBL1/SIOPEN trial experience

Written By Carla Aguilera

P Berlanga, C Pasqualini, U Pötschger, C Sangüesa, M R Castellani, A Cañete, R Luksch, M Elliot, G Schreier, M Kropf, D Morgenstern, V Papadakis, S Ash, E Ruud, P Brock, A Wieczorek, P Kogner, T Trahair, P Ambros, T Boterberg, V Castel, D Valteau-Couanet, R Ladenstein

 Eur J Cancer. 2021 Feb;144:1-8. doi: 10.1016/j.ejca.2020.10.020. Epub 2020 Dec 11.

Carla Aguilera
Previous

Randomised trial of two induction therapy regimens for high-risk neuroblastoma HR-NBL1.5 …
Next

Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable MYCN-Nonamplified Neuroblastomas.